Migraine and Headache Studies
Open access
Peer reviewed
Abstract
Abstract
BACKGROUND: Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are effective migraine-specific preventive therapies; however, access remains limited in many low- and middle-income countries (LMICs). In such settings, oral migraine preventive medications (OMPMs) continue to serve as the foundation of preventive care. The association between baseline preventive regimens and real-world escalation to CGRP mAbs has not been well characterized. METHODS: We conducted a single-center retrospective cohort study of adults with migraine attending a university-based headache clinic in Thailand between January 2021 and December 2023. Participants with at least one baseline OMPM, no prior CGRP mAb exposure, and at least 6 months of follow-up were included. Multivariable Cox proportional hazards models, adjusted for age, sex, and migraine subtype, were used to examine associations between baseline OMPM classes and CGRP mAb initiation. A secondary analysis evaluated factors associated with discontinuation of baseline OMPMs. RESULTS: Among 80 participants, 16 (20.0%) initiated CGRP mAbs over 11,554 person-days of follow-up, with a median time to initiation of 44.5 days. Baseline use of beta-blockers (BBs) or tricyclic antidepressants (TCAs) was independently associated with a lower likelihood of CGRP mAb initiation (BB: adjusted hazard ratio [aHR] 0.17, 95% CI 0.04-0.66; TCA: aHR 0.12, 95% CI 0.02-0.57). In secondary analyses, baseline BB use was also associated with greater persistence with preventive therapy (aHR for discontinuation 0.24, 95% CI 0.09-0.64). CONCLUSIONS: Baseline oral preventive regimens were associated with differing likelihoods of switching to CGRP mAbs in this LMIC setting. Optimizing oral preventive treatment strategies remains essential in settings where access to CGRP-targeted therapies is limited, either due to unavailability or lack of reimbursement.
Direct answer
What can I do from this paper page?
Use this page to scan "Associations between oral migraine preventive regimens and CGRP monoclonal antibody initiation: real-world evidence from a resource-limited setting" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Migraine and Headache Studies research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Thanprasertsuk2026Associations,
title = {Associations between oral migraine preventive regimens and CGRP monoclonal antibody initiation: real-world evidence from a resource-limited setting},
author = {Sekh Thanprasertsuk and Akarin Hiransuthikul and Sirawit Roongrojwittayakul and Thanakit Pongpitakmetha and Wanakorn Rattanawong and Prakit Anukoolwittaya},
journal = {BMC Neurology},
year = {2026},
doi = {10.1186/s12883-026-05030-0},
url = {https://doi.org/10.1186/s12883-026-05030-0}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Migraine and Headache Studies research papers?
Follow Migraine and Headache Studies research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Associations between oral migraine preventive regimens and CGRP monoclonal antibody initiation: real-world evidence from a resource-limited setting. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app